[{"id":"49b56574-d546-4ca7-a49a-b03317d41c4c","acronym":"ISIdE","url":"https://clinicaltrials.gov/study/NCT05552001","created_at":"2023-09-05T19:11:08.766Z","updated_at":"2024-07-02T16:35:00.022Z","phase":"Phase 3","brief_title":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT05552001 - ISIdE","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • PD-1","pipe":" | ","alterations":" ER expression • PGR expression • ER amplification • PD-1 positive","tags":["HER-2 • ER • PGR • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • PGR expression • ER amplification • PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-30"},{"id":"72423788-4e7b-4c6c-8ed9-05141f3ec24f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06082570","created_at":"2023-10-14T01:13:19.359Z","updated_at":"2024-07-02T16:35:33.523Z","phase":"Phase 1/2","brief_title":"A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients","source_id_and_acronym":"NCT06082570","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-13"},{"id":"8c71eabb-cd74-4759-82b6-0d000c43a43f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04571892","created_at":"2021-01-18T21:49:50.079Z","updated_at":"2024-07-02T16:35:50.835Z","phase":"Phase 1/2","brief_title":"A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors","source_id_and_acronym":"NCT04571892","lead_sponsor":"Shanghai East Hospital","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ScTIL210"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-12"},{"id":"5b7aca1a-24f8-4440-bac3-cb40edc7fa7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05730361","created_at":"2023-02-15T18:03:22.791Z","updated_at":"2024-07-02T16:35:55.454Z","phase":"Phase 1","brief_title":"Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors","source_id_and_acronym":"NCT05730361","lead_sponsor":"Peking University","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ScTIL210"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-02-15"},{"id":"4cd4d549-9fc1-46f8-8fc0-b58e00e888d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05499715","created_at":"2022-11-08T19:21:33.288Z","updated_at":"2024-07-02T16:36:05.605Z","phase":"Phase 1","brief_title":"A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy of ScTIL Injection (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05499715","lead_sponsor":"Chinese Academy of Medical Sciences","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ScTIL"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 08/30/2024","study_completion_date":" 08/30/2024","last_update_posted":"2022-08-12"},{"id":"1b165c6f-ea64-459f-b1f5-2f8e3a98fc1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02573259","created_at":"2021-01-17T17:43:00.102Z","updated_at":"2024-07-02T16:36:19.570Z","phase":"Phase 1","brief_title":"A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors","source_id_and_acronym":"NCT02573259","lead_sponsor":"Pfizer","biomarkers":" PD-L1 • ALK • CD8 • PD-1 • CCR7","pipe":" | ","alterations":" EGFR mutation • ALK mutation • PD-1 positive","tags":["PD-L1 • ALK • CD8 • PD-1 • CCR7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumrad (sasanlimab)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 11/19/2020","primary_completion_date":" 11/19/2020","study_txt":" Completion: 11/19/2020","study_completion_date":" 11/19/2020","last_update_posted":"2021-12-13"},{"id":"160c0a88-af23-4417-a290-001e79ab98cf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04913480","created_at":"2021-06-04T14:53:25.916Z","updated_at":"2024-07-02T16:36:29.483Z","phase":"Phase 2","brief_title":"SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma","source_id_and_acronym":"NCT04913480","lead_sponsor":"The University of Hong Kong","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 positive","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2021-06-04"}]